http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Jun 2026 16:09:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++144++++++++Avalo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Goldman+Jonathan/26591685.html si-local-file:///var/storage/secattach/20260602/26591685.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Avalo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Goldman+Jonathan/26591685.html Tue, 02 Jun 2026 16:09:00 -0400 AVTX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Avalo+Therapeutics%2C+Inc.++For%3A+May+28++Filed+by%3A+Doyle+Mittie/26583547.html si-local-file:///var/storage/secattach/20260601/26583547.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Avalo+Therapeutics%2C+Inc.++For%3A+May+28++Filed+by%3A+Doyle+Mittie/26583547.html Mon, 01 Jun 2026 16:08:00 -0400 AVTX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Avalo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Deep+Track+Capital%2C+LP/26575900.html si-local-file:///var/storage/secattach/20260529/26575900.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Avalo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Deep+Track+Capital%2C+LP/26575900.html Fri, 29 May 2026 16:37:00 -0400 AVTX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Avalo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Point72+Asset+Management%2C+L.P./26551198.html si-local-file:///var/storage/secattach/20260526/26551198.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Avalo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Point72+Asset+Management%2C+L.P./26551198.html Tue, 26 May 2026 17:10:00 -0400 AVTX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Avalo+Therapeutics%2C+Inc.++For%3A+May+21++Filed+by%3A+Doyle+Mittie/26550020.html si-local-file:///var/storage/secattach/20260526/26550020.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Avalo+Therapeutics%2C+Inc.++For%3A+May+21++Filed+by%3A+Doyle+Mittie/26550020.html Tue, 26 May 2026 16:10:00 -0400 AVTX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Avalo+Therapeutics%2C+Inc.++For%3A+May+21++Filed+by%3A+NEIL+GARRY+ARTHUR/26550023.html si-local-file:///var/storage/secattach/20260526/26550023.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Avalo+Therapeutics%2C+Inc.++For%3A+May+21++Filed+by%3A+NEIL+GARRY+ARTHUR/26550023.html Tue, 26 May 2026 16:10:00 -0400 AVTX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Avalo+Therapeutics%2C+Inc.++For%3A+May+21++Filed+by%3A+Riley+Jennifer/26550026.html si-local-file:///var/storage/secattach/20260526/26550026.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Avalo+Therapeutics%2C+Inc.++For%3A+May+21++Filed+by%3A+Riley+Jennifer/26550026.html Tue, 26 May 2026 16:10:00 -0400 AVTX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Avalo+Therapeutics%2C+Inc.++For%3A+May+21++Filed+by%3A+VARKI+PAUL/26550027.html si-local-file:///var/storage/secattach/20260526/26550027.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Avalo+Therapeutics%2C+Inc.++For%3A+May+21++Filed+by%3A+VARKI+PAUL/26550027.html Tue, 26 May 2026 16:10:00 -0400 AVTX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Avalo+Therapeutics%2C+Inc.++For%3A+May+21++Filed+by%3A+Sullivan+Christopher+Ryan/26550030.html si-local-file:///var/storage/secattach/20260526/26550030.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Avalo+Therapeutics%2C+Inc.++For%3A+May+21++Filed+by%3A+Sullivan+Christopher+Ryan/26550030.html Tue, 26 May 2026 16:10:00 -0400 AVTX http://www.streetinsider.com/Press+Releases/Avalo+Therapeutics+Announces+Inducement+Grant+to+New+Employee+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26541343.html <p align="justify">WAYNE, PA., May 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that the Company granted an inducement award consisting of an option to purchase 34,000 shares of its common stock to one new employee (the “Option”). The award was approved by the Compensation Committee of the Board of Directors as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).</p> <p align="justify">The Option was granted on May 21, http://www.streetinsider.com/Press+Releases/Avalo+Therapeutics+Announces+Inducement+Grant+to+New+Employee+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26541343.html Fri, 22 May 2026 16:01:00 -0400 AVTX http://www.streetinsider.com/Globe+Newswire/Avalo+Therapeutics+Announces+Inducement+Grant+to+New+Employee+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26541343.html <p align="justify">WAYNE, PA., May 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that the Company granted an inducement award consisting of an option to purchase 34,000 shares of its common stock to one new employee (the “Option”). The award was approved by the Compensation Committee of the Board of Directors as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).</p> <p align="justify">The Option was granted on May 21, http://www.streetinsider.com/Globe+Newswire/Avalo+Therapeutics+Announces+Inducement+Grant+to+New+Employee+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26541343.html Fri, 22 May 2026 16:01:00 -0400 AVTX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Avalo+Therapeutics%2C+Inc.++For%3A+May+15++Filed+by%3A+Doyle+Mittie/26521209.html si-local-file:///var/storage/secattach/20260519/26521209.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Avalo+Therapeutics%2C+Inc.++For%3A+May+15++Filed+by%3A+Doyle+Mittie/26521209.html Tue, 19 May 2026 16:10:00 -0400 AVTX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Avalo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Logos+Global+Management+LP/26508283.html si-local-file:///var/storage/secattach/20260515/26508283.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Avalo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Logos+Global+Management+LP/26508283.html Fri, 15 May 2026 18:41:00 -0400 AVTX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Avalo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26506926.html si-local-file:///var/storage/secattach/20260515/26506926.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Avalo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26506926.html Fri, 15 May 2026 16:42:00 -0400 AVTX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Avalo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+ORBIMED+ADVISORS+LLC/26506845.html si-local-file:///var/storage/secattach/20260515/26506845.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Avalo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+ORBIMED+ADVISORS+LLC/26506845.html Fri, 15 May 2026 16:40:00 -0400 AVTX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Avalo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+BIOTECHNOLOGY+VALUE+FUND+L+P/26505002.html si-local-file:///var/storage/secattach/20260515/26505002.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Avalo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+BIOTECHNOLOGY+VALUE+FUND+L+P/26505002.html Fri, 15 May 2026 16:07:00 -0400 AVTX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Avalo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Caligan+Partners+LP/26501613.html si-local-file:///var/storage/secattach/20260515/26501613.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Avalo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Caligan+Partners+LP/26501613.html Fri, 15 May 2026 10:31:00 -0400 AVTX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Avalo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+T.+Rowe+Price+Investment+Management%2C+Inc./26501286.html si-local-file:///var/storage/secattach/20260515/26501286.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Avalo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+T.+Rowe+Price+Investment+Management%2C+Inc./26501286.html Fri, 15 May 2026 10:08:00 -0400 AVTX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Avalo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Avoro+Capital+Advisors+LLC/26499938.html si-local-file:///var/storage/secattach/20260515/26499938.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Avalo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Avoro+Capital+Advisors+LLC/26499938.html Fri, 15 May 2026 08:15:00 -0400 AVTX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Avalo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Affinity+Asset+Advisors%2C+LLC/26494905.html si-local-file:///var/storage/secattach/20260514/26494905.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Avalo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Affinity+Asset+Advisors%2C+LLC/26494905.html Thu, 14 May 2026 16:10:00 -0400 AVTX http://www.streetinsider.com/Analyst+PT+Change/Avalo+Therapeutics+Inc.+%28AVTX%29+PT+Lowered+to+%2435+at+H.C.+Wainwright/26489504.html (Updated - May 14, 2026 6:44 AM EDT) <p>H.C. Wainwright analyst Mitchel Kapoor lowered the price target on Avalo Therapeutics Inc. (NASDAQ: AVTX) to $35.00 (from $40.00) while maintaining a Buy rating.</p><p>The analyst commented: "The LOTUS top-line results showed that abdakibart is active in hidradenitis suppurativa (HS), but did not definitively displace AbbVie’s lutikizumab on HiSCR75 depth or placebo-adjusted separation. The high-dose/once-monthly abdakibart arm generated a +17.2-point HiSCR75 Δ vs. placebo (42.9% vs. 25.6%), below lutikizumab Q2W’s +28.2-point Δ (45.9% vs. 17.5%) in anti-TNF failures and lutikizumab QW’s +21.0-point Δ (38.5% vs. 17.5%) in AbbVie’s randomized Phase 2 study. Abdakibart also http://www.streetinsider.com/Analyst+PT+Change/Avalo+Therapeutics+Inc.+%28AVTX%29+PT+Lowered+to+%2435+at+H.C.+Wainwright/26489504.html Thu, 14 May 2026 06:44:15 -0400 AVTX http://www.streetinsider.com/Analyst+Comments/Avalo+Therapeutics+Inc.+%28AVTX%29+PT+Lowered+to+%2435+at+H.C.+Wainwright/26489504.html (Updated - May 14, 2026 6:44 AM EDT) <p>H.C. Wainwright analyst Mitchel Kapoor lowered the price target on Avalo Therapeutics Inc. (NASDAQ: AVTX) to $35.00 (from $40.00) while maintaining a Buy rating.</p><p>The analyst commented: "The LOTUS top-line results showed that abdakibart is active in hidradenitis suppurativa (HS), but did not definitively displace AbbVie’s lutikizumab on HiSCR75 depth or placebo-adjusted separation. The high-dose/once-monthly abdakibart arm generated a +17.2-point HiSCR75 Δ vs. placebo (42.9% vs. 25.6%), below lutikizumab Q2W’s +28.2-point Δ (45.9% vs. 17.5%) in anti-TNF failures and lutikizumab QW’s +21.0-point Δ (38.5% vs. 17.5%) in AbbVie’s randomized Phase 2 study. Abdakibart also http://www.streetinsider.com/Analyst+Comments/Avalo+Therapeutics+Inc.+%28AVTX%29+PT+Lowered+to+%2435+at+H.C.+Wainwright/26489504.html Thu, 14 May 2026 06:44:15 -0400 AVTX http://www.streetinsider.com/Analyst+PT+Change/Avalo+Therapeutics+Inc.+%28AVTX%29+PT+Raised+to+%2445+at+Mizuho/26489472.html Mizuho analyst Joseph Catanzaro raised the price target on Avalo Therapeutics Inc. (NASDAQ: AVTX) to $45.00 (from $39.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Avalo+Therapeutics+Inc.+%28AVTX%29+PT+Raised+to+%2445+at+Mizuho/26489472.html Thu, 14 May 2026 06:37:51 -0400 AVTX http://www.streetinsider.com/Analyst+PT+Change/Avalo+Therapeutics+Inc.+%28AVTX%29+PT+Lowered+to+%2455+at+Citizens%2C+Reflecting+Recent+Equity+Financing/26488604.html <p>Citizens analyst Jason Butler lowered the price target on Avalo Therapeutics Inc. (NASDAQ: AVTX) to $55.00 (from $62.00) while maintaining a Market Outperform rating.</p><p>The analyst commented, "Positive Phase 2 LOTUS results support advancement to registrational studies; we reiterate our Market Outperform rating on Avalo Therapeutics though lower our risk-adjusted, DCFderived price target to $55 from $62 to reflect the recent equity financing. This morning, Avalo reported 1Q26 financial results and business updates, underscoring its plans to advance abdakibart into registrational Phase 3 studies. Recall, the Phase 2 LOTUS trial demonstrated positive results (our note here) with, in our view, a http://www.streetinsider.com/Analyst+PT+Change/Avalo+Therapeutics+Inc.+%28AVTX%29+PT+Lowered+to+%2455+at+Citizens%2C+Reflecting+Recent+Equity+Financing/26488604.html Thu, 14 May 2026 04:48:16 -0400 AVTX http://www.streetinsider.com/Analyst+Comments/Avalo+Therapeutics+Inc.+%28AVTX%29+PT+Lowered+to+%2455+at+Citizens%2C+Reflecting+Recent+Equity+Financing/26488604.html <p>Citizens analyst Jason Butler lowered the price target on Avalo Therapeutics Inc. (NASDAQ: AVTX) to $55.00 (from $62.00) while maintaining a Market Outperform rating.</p><p>The analyst commented, "Positive Phase 2 LOTUS results support advancement to registrational studies; we reiterate our Market Outperform rating on Avalo Therapeutics though lower our risk-adjusted, DCFderived price target to $55 from $62 to reflect the recent equity financing. This morning, Avalo reported 1Q26 financial results and business updates, underscoring its plans to advance abdakibart into registrational Phase 3 studies. Recall, the Phase 2 LOTUS trial demonstrated positive results (our note here) with, in our view, a http://www.streetinsider.com/Analyst+Comments/Avalo+Therapeutics+Inc.+%28AVTX%29+PT+Lowered+to+%2455+at+Citizens%2C+Reflecting+Recent+Equity+Financing/26488604.html Thu, 14 May 2026 04:48:16 -0400 AVTX